Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB007 in Uncontrolled Allergic Asthma
NCT03468790Phase 3Completed
- Sponsor
- Shanghai Biomabs Pharmaceuticals
- Start
- May 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in allergic asthma, sponsored by Shanghai Biomabs Pharmaceuticals. Started May 2018; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT03468790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468790.